- 收听数
- 0
- 听众数
- 7
- 最后登录
- 2024-11-8
- QQ
- UID
- 9301
- 阅读权限
- 10
- 帖子
- 1189
- 精华
- 0
- 在线时间
- 380 小时
- 注册时间
- 2014-5-1
- 科研币
- 2
- 速递币
- 21
- 娱乐币
- 1794
- 文献值
- 0
- 资源值
- 0
- 贡献值
- 0
|
5速递币
题名 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. | 链接 | http://link.springer.com/article/10.1007%2Fs10549-013-2589-8 |
|
|